Menu Icon
Refresh Miami Logo
Search Icon
Sign Up Sign In

Biobeat raises a $50M Series B for its US expansion

Nancy Dahlberg
Nancy Dahlberg
PinLinkedIn

Biobeat Technologies developed the first FDA-cleared, 24-hour ambulatory blood pressure monitoring  (ABPM) system that is a patch-worn, cuff-less solution for diagnosis and treatment of hypertension. Biobeat expands the use of ABPM for hypertensive patients and providing 24-hour blood pressure data. Its system enables comfort and uninterrupted sleep for patients while capturing critical nighttime BP measurements.

This week the Israel-and Boca Raton-based startup announced the closing of a $50 million Series B equity round. The financing was led by new investors Ally Bridge Group, OrbiMed Advisors and Elevage Medical and included participation from a strategic investor, the company said. As part of the transaction, Steven Plachtyna of Ally Bridge, Dina Chaya of OrbiMed and Evan Melrose of Elevage have joined Biobeat’s Board of Directors.

Biobeat, founded in 2016, will use the funding to expand commercialization in the US, including its sales team.

Arik Ben Ishay

Arik Ben Ishay, co-founder and CEO of BioBeat, said the time has finally arrived to make ABPM a true standard of care to help diagnosis and titrate anti-hypertensive medications.

“What started as a shared vision between myself, Johanan May, and Israel Sarussi has reached a transformative milestone. This isn’t just a financial milestone; it’s a mandate to change the lives of the 120 million people in the U.S. struggling with hypertension. The era of the uncomfortable, disruptive blood pressure cuff is ending. The future is seamless, 24-hour, cuff-less monitoring,” Ben Ishay shared on LinkedIn.

Biobeat, a graduate of the Global Ventures program at the Research Park at FAU, set up its US hub in Boca Raton last year. Ben Ishay has said his team chose South Florida, partly because the area has some of the highest rates of high blood-pressure in the US, and it hosts a leading US medical facility focused on the condition: the University of Miami Health System’s Comprehensive Hypertension Center.

“There’s also something I see in the people in Miami that I don’t see in New York: they’re very warm, want to do business, and in the medical community, are very open to innovation,” Ben Ishay said in a 2025 interview with Refresh Miami.

Indeed, Biobeat is one of hundreds of medical technology startups and larger companies growing in the Miami-Fort Lauderdale metro region. For at least the past four years, the medtech sector has been the second most active sector in South Florida venture capital, behind only fintech.

Biobeat also represents another growing trend: More and more, when it’s time for US expansion, international companies are choosing the Miami metro area to base their operations.

 READ MORE IN REFRESH MIAMI:

Nancy Dahlberg
Latest posts by Nancy Dahlberg (see all)